Page 49 - Read Online

Della Porta et al. Comparison of p53 and prohibitin expression

microenvironment observed in the sequence of HCV, Res 2005;15:430-8.
CIR, and HCC. 11. Chu L, Gu J, He Z, Xiao T, Liu X. Adenoviral vector expressing
CYLD augments antitumor activity of TRAIL by suppression of NF-
Authors’ contributions kappaB survival signaling in hepatocellular carcinoma. Cancer Biol
Ther 2006;5:615-22.
Casuistic retrieval and samples analysis: L.M. Della Porta 12. Jiang YF, He B, Li NP, Ma J, Gong GZ, Zhang M. The oncogenic
Statistical analysis and writing: F.S. Ramalho role of NS5A of hepatitis C virus is mediated by up-regulation of
Samples analysis and discussion: C.A. Oliveira survivin gene expression in the hepatocellular cell through p53 and
Histological and immunohistochemical preparations NF-κB pathways. Cell Biol Int 2011;35:1225-32.
and analysis: D.M. Silva 13. Nuell MJ, Stewart DA, Walker L, Friedman V, Wood CM,
Owens GA, Smith JR, Schneider EL, Dell’ Orco R, Lumpkin CK,
Southwestern histochemistry and analysis: M.J. Augusto Danner DB, McClung JK. Prohibitin, an evolutionarily conserved
Paper scientific design and writing: L.N.Z. Ramalho intracellular protein that blocks DNA synthesis in normal fibroblasts
and HeLa cells. Mol Cell Biol 1991;11:1372-81.
Financial support and sponsorship 14. Mishra S, Murphy LC, Murphy LJ. The prohibitins: emerging roles
in diverse functions. J Cell Mol Med 2006;10:353-63.
This work was supported by Fundação de Amparo 15. Ko KS, Tomasi ML, Iglesias-Ara A, French BA, French SW, Ramani
à Pesquisa do Estado de São Paulo (FAPESP)- K, Lozano JJ, Oh P, He L, Stiles BL, Li TW, Yang H, Martínez-
nº2010/20895-4, Conselho Nacional de Desenvolvimento Chantar ML, Mato JM, Lu SC. Liver-specific deletion of prohibitin
Científico e Tecnológico (CNPq)-nº302547/2012-6 and 1 results in spontaneous liver injury, fibrosis, and hepatocellular
Fundação de Amparo à Fundação de Apoio ao Ensino, carcinoma in mice. Hepatology 2010;52:2096-108.
Pesquisa e Assistência (FAEPA). 16. Tsutsumi T, Matsuda M, Aizaki H, Moriya K, Miyoshi H, Fujie
H, Shintani Y, Yotsuyanagi H, Miyamura T, Suzuki T, Koike K.
Conflict of interests Proteomics analysis of mitochondrial proteins reveals overexpression
of a mitochondrial protein chaperon, prohibitin, in cells expressing
There are no conflicts of interests. hepatitis C virus core protein. Hepatology 2009;50:378-86.
17. Rajalingam K, Rudel T. Ras-Raf signaling needs prohibitin. Cell
Patient consent Cycle 2005;4:1503-5.
Each patient was informed of the study and gave their 18. Cong X, Lu C, Huang X, Yang D, Cui X, Cai J, Lv L, He S, Zhang
Y, Ni R. Increased expression of glycinamide ribonucleotide
consent. transformylase is associated with a poor prognosis in hepatocellular
carcinoma, and it promotes liver cancer cell proliferation. Hum
Ethics approval Pathol 2014;45:1370-8.
The study was approved by the local Ethics Committee 19. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L,
Urdea MS, Kolberg JA, Lau JY. Activation of tumor necrosis factor-
(nº1611/2011). alpha system in chronic hepatitis C virus infection. Dig Dis Sci
1997;42:2487-94.
REFERENCES 20. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W,
Theilmann L, Singer MV, Rossol S. Induction of tumour necrosis
1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118- factor (TNF) receptor type p55 and p75 in patients with chronic
27. hepatitis C virus (HCV) infection. Clin Exp Immunol 1998;111:269-77.
2. Shiraha H, Yamamoto K, Namba M. Human hepatocyte 21. You LR, Chen CM, Lee YH. Hepatitis C virus core protein enhances
carcinogenesis (review). Int J Oncol 2013;42:1133-8. NF-kappaB signal pathway triggering by lymphotoxin-beta receptor
3. Gilmore TD. Introduction to NF-kappaB: Players, pathways, ligand and tumor necrosis factor alpha. J Virol 1999;73:1672-81.
perspectives. Oncogene 2006;25:6680-4. 22. Braz MM, Ramalho FS, Cardoso RL, Zucoloto S, Costa RS, Ramalho
4. Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. LN. Slight activation of nuclear factor kappa-B is associated with
Cancer Lett 2005;229:157-69. increased hepatic stellate cell apoptosis in human schistosomal
5. Guan YS, He Q, Wang MQ, Li P. Nuclear factor kappa B and fibrosis. Acta Trop 2010;113:66-71.
hepatitis viruses. Expert Opin Ther Targets 2008;12:265-80. 23. Luedde T, Schwabe RF. NF-κB in the liver-linking injury, fibrosis
6. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol
signals in liver inflammation. J Hepatol 2013;59:583-94. 2011;8:108-18.
7. Liedtke C, Trautwein C. The role of TNF and Fas dependent 24. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC.
signaling in animal models of inflammatory liver injury and liver Apoptosis induced in normal human hepatocytes by tumor necrosis
cancer. Eur J Cell Biol 2012;91:582-9. factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
8. Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver 25. Yeh CH, Yang YY, Huang YF, Chow KC, Chen MF. Induction of
disease: cross-talk between the NF-kappaB and JNK pathways. Biol apoptosis in human Hep3B hepatoma cells by norcantharidin through
Chem 2009;390:965-76. a p53 independent pathway via TRAIL/DR5 signal transduction.
9. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha- Chin J Integr Med 2012;18:676-82.
induced liver injury: role of IKK, JNK, and ROS pathways. Am J 26. Martin J, Dufour JF. Tumor suppressor and hepatocellular carcinoma.
Physiol Gastrointest Liver Physiol 2006;290:G583-9. World J Gastroenterol 2008;14:1720-33.
10. Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, 27. Kasprzak A, Adamek A, Przybyszewska W, Czajka A, Olejniczak
Ch´En P, Xu XN, Jin BQ, Pezzella F, Screaton GR. Expression of K, Juszczyk J, Biczysko W, Zabel M. p53 immunocytochemistry and
TRAIL and TRAIL receptors in normal and malignant tissues. Cell TP53 gene mutations in patients with chronic hepatitis C virus (HCV)
Hepatoma Research ¦ Volume 3 ¦ February 28, 2017 41